Specific B-cell tolerance toward donor blood group antigens develops in infants after ABO-incompatible heart transplantation, whereas their immune response toward protein antigens such as HLA has not been investigated. We assessed de novo HLA-antibodies in 122 patients after pediatric thoracic transplantation (28 ABO-incompatible) and 36 controls. Median age at transplantation was 1.7 years (1 day to 17.8 year) and samples were collected at median 3.48 years after transplantation. Antibodies were detected against HLA-class I in 21 patients (17.2%), class II in 18 (14.8%) and against both classes in 10 (8.2%). Using singleantigen beads, donor-specific antibodies (DSAs) were identified in six patients (all class II, one additional class I). Patients with DSAs were significantly older at time of transplantation. In patients who had undergone pretransplant cardiac surgeries, class II antibodies were more frequent, although use of homografts or mechanical heart support had no influence. DSAs were absent in ABO-incompatible recipients and class II antibodies were significantly less frequent than in children with ABO-compatible transplants. This difference was present also when comparing only children transplanted below 2 years of age. Therefore, tolerance toward the donor blood group appears to be associated with an altered response to HLA beyond agerelated effects.
Introduction

Infants differ fundamentally in their capacity to mount immune responses to polysaccharide antigens (i.e. blood group antigens, ABO) versus protein antigens (i.e. HLA). Because infants do not normally manifest responses to foreign blood groups, ABO-incompatible heart transplantation was found to be a safe clinical approach to enhance donor availability (1). After ABO-incompatible transplantation, a majority of recipients develop spontaneous B-cell tolerance to the donor blood group antigens, showing a pattern of persistent absence of antibodies toward the donor blood group, whereas antibodies toward other polysaccharide antigens, such as the nondonor blood group, develop normally (2). An analysis of the underlying mechanisms of tolerance in this setting demonstrated absence of active B cells specific to the donor blood group (3). However, immune responses also vary with age. Young animals respond poorly if at all to challenge by certain antigens. Moreover, Medawar and colleagues demonstrated in the 1950s that exposure of newborn animals to allogeneic cells induced a state of specific immune tolerance to subsequent antigen exposure in skin grafts (4). Whether and to what extent acceptance of grafts by young recipients reflects immaturity and hence absence of responses, and to what extent it reflects tolerance, is poorly understood. We now explore how tolerance or immunologic immaturity may affect responses to other donor antigens, such as HLA, proteins to which human infants are normally capable of mounting an immune response.
Anti-HLA antibodies are associated with hyperacute and acute antibody-mediated rejection if present at the time of transplantation (5). De novo antibodies that develop after transplantation have been shown to accelerate graft vasculopathy and lead to decreased graft survival in adults after heart
and other solid organ transplants (7) . In children requiring heart transplantation, smaller studies have described the same consequences, especially if the antibodies were directed toward specific HLA present on the donor organ (8, 9) . However, most of the available pediatric data concern patients who were presensitized or whose antibody status was unknown prior to transplantation.
The purpose of this study was to determine if children after ABO-incompatible transplantation show differences when compared to ABO-compatible 
Results
Patient characteristics
The demographic and clinical history of the patient cohort is shown in (14, 15) . responses of early childhood. In the heart, HLA class II expression is found predominantly on vascular endothelium (17) whereas cardiomyocytes show only weak expression of both HLA classes (18) . 
In addition to vascular endothelium, expression of HLA class II molecules is generally limited to highly specialized cells of the immune system such as macrophages, dendritic cells and B cells (19). In this context, the role of B cells as specific antigenpresenting cells, in addition to their function as a main component for initiation of antibody-mediated rejection (20), may be crucial. The interaction of B and T cells has been found to be less efficient in early childhood than later, for example as in reduced expression of CD40 and CD40 ligand (CD154) (21). Studies on infection and vacci-
